Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Go back to Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer| Pfizer Inc. (NYSE: PFE) | Delayed: 27.76 +0.04 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.72 | 52 Week High | $37.39 | |||
| Open | $28.08 | 52 Week Low | $28.25 | |||
| Day High | $28.19 | P/E | 16.82 | |||
| Day Low | $27.69 | EPS | $1.65 | |||
| Volume | 13,931,300 | |||||
